DAVY VIEW

Venn has announced a partnership with Carrick Therapeutics, an Ireland and UK based biotech company developing treatments for aggressive forms of cancer. It has built a network of partners to progress its technology portfolio and Venn is joining this network as an outsourced provider of early development and clinical research capabilities. This new client is ideal for Venn – it is an innovative company, focusing on its core technology in the high value, high growth oncology market, while working on an outsourced basis with partners like Venn. Venn has the early stage and clinical research capabilities to support the development of its products through the development lifecycle.